Brain

ŌURA Announces Two New Heart Health Features, Moving Deeper into Preventative Health

New Cardiovascular Age and Cardio Capacity capabilities further establish ŌURA as a personal health companion for improving healthspan and longevitySAN…

8 months ago

Hyperfine, Inc. to Expand Global Market Reach with Appointment of International Distributors in Key European Markets

- Distributors appointed in France, the United Kingdom, and Italy - Industry veteran Enrico Barini joins as International Business Development…

8 months ago

Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan(R) (rifaximin)

Xifaxan is the first and only FDA approved medication for the reduction in risk of OHE recurrence in adultsOvert Hepatic…

8 months ago

Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan(R) (rifaximin)

Xifaxan is the first and only FDA approved medication for the reduction in risk of OHE recurrence in adultsOvert Hepatic…

8 months ago

Halberd’s Traumatic Brain Injury Treatment Projects Align with New U.S. House Bill

Daniel J. Harvey and Adam Lambert Improving Servicemember Transition to Reduce Veteran Suicide Act, passed the U.S. House unanimously.JACKSON CENTER,…

8 months ago

Halberd’s Traumatic Brain Injury Treatment Projects Align with New U.S. House Bill

Daniel J. Harvey and Adam Lambert Improving Servicemember Transition to Reduce Veteran Suicide Act, passed the U.S. House unanimously.JACKSON CENTER,…

8 months ago

IRLAB Publishes Interim Eeport for the Period January-March 2024

GOTHENBURG, SWEDEN / ACCESSWIRE / May 8, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, May 8, 2024 - IRLAB Therapeutics…

8 months ago

Standout Digital Health and Medical Technology Innovators Honored in 2024 MedTech Breakthrough Awards Program

International Annual Awards Program Recognizes Outstanding Health & Medical Technology Products and CompaniesLOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) --…

8 months ago

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23

HOUSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to…

8 months ago

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension

- FDA indicated IkT-001Pro can be considered a New Molecular Entity and is eligible for exclusivity designations in Pulmonary Arterial…

8 months ago